BOSTON, July 31,
2024 /PRNewswire/ -- Recently,
Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui
Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic
collaboration agreement. The cooperative efforts will focus on
preclinical evaluation of new drug
modalities, particularly ADCs, small nucleic acids, and CGT
(cell and gene therapy) drugs. The goal of this partnership is
to advance the innovation of the Chinese pharmaceutical industry to
compete on an international level.
The elevated commitment to collaboration between Medicilon
and Hengrui Pharma builds upon the solid foundation from years of
experience and well-established trust. The organizations
plan to integrate Medicilon's preclinical R&D expertise with
Hengrui Pharma's innovative strategies and market influence.
Medicilon will leverage its technological advantages in drug
discovery and development to provide Hengrui Pharma with a range of
preclinical services, focusing on efficacy testing,
pharmacokinetics, and toxicology studies for new drug modalities. Medicilon and
Hengrui Pharma will combine efforts to generate breakthroughs in
pharmaceutical therapies.
The atmosphere of the exchange was enthusiastic and
congenial. Hengrui Pharma's Vice General Manager &
Global R&D President Lianshan Zhang, along with other
executives, visited Medicilon's Pudong Chuansha Park. They were
welcomed by Medicilon's CEO Chunlin
Chen and key team members.
During the visit, Medicilon's R&D Team introduced their
one-stop preclinical services platform for pharmaceutical R&D.
They highlighted the Medicilon's capabilities and technical
strengths in safety evaluation, pharmacology, and pharmacokinetics,
with special attention to PROTAC, ADC, nucleic acids, bispecific
antibodies, peptides, vaccines, and CGT.
Hengrui Pharma's Vice General Manager & Global R&D
President Lianshan Zhang stated, "Medicilon possesses robust
innovation capabilities and service quality in this field, making
it a trusted CRO partner. The collaboration between Hengrui Pharma
and Medicilon not only acknowledges past achievements but also
represents a deep exploration of future collaboration potential and
forward-looking strategic planning."
Medicilon's Founder & CEO Chunlin
Chen stated, "Medicilon and Hengrui Pharma firmly
believe that, through close collaboration, the process of drug
R&D will be accelerated in the future, contributing to the
innovative development of the global pharmaceutical industry."
Website: https://www.medicilon.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medicilon-and-hengrui-pharma-deepen-strategic-collaboration-to-support-innovation-in-adcs-small-nucleic-acids-and-cgt-drugs-302211184.html
SOURCE Medicilon Inc.